1706147601
Sepsis continues to be responsible for 11 million deaths per year in Europe. A paper published by the European EGIS consortium in The Lancet Respiratory Medicine. helps identify all techniques to assess the immune response of patients who develop the disease and advance early diagnosis and more personalized treatment
The principal investigator of the BioSepsis group of the Salamanca Biomedical Research Institute (IBSAL), Jesús Bermejo, co-led this groundbreaking work from the European consortium EGIS, “which represents a significant advance in precision medicine for the treatment of sepsis.”
The work identifies all existing techniques for assessing the immune response in the disease This facilitates early diagnosis and the application of more individualized treatment for each patient.
Currently, the mortality rate for sepsis, the most serious form of infection, is between 10 and 20%, and for septic shock it rises to 40%, causing up to 11 million deaths annually worldwide, about 17,000 in Spain.
In this context, as Dr. Bermejo, also principal investigator at CIBER and associate professor at the Faculty of Medicine at the University of Salamanca (USAL), explains that “in sepsis There are very clear immunological changes that have a lot to do with the pathophysiology, but it is strange that we have not been able to evaluate them yet.” to optimize the treatment of these patients.
Now, after two years of intensive work, experts from various specialties of the European Sepsis Immunology Group (EGIS), coordinated by the IBSAL and the Jena Sepsis Care and Control Center (Germany), have managed to bring together all the clinical tools available in hospital centers and others will soon be implemented with which to perform the “immunological photo”, which will allow us to better detect when an infection is progressing towards sepsis, and at the same time to start earlier and better select the treatment. . “We have already learned from the world of cancer that treatment must be personalized, because with sepsis it should be the same“, assures Dr. Jesús Bermejo, also senior author of the article published in The Lancet Respiratory Medicine together with Sara Cajander, Fabienne Venet, Matthijs Kox or Joerg C Schefold.
It is a set of valid techniques for analyzing the value of various biomarkers that can be measured in the blood, using simple procedures ranging from flow cytometry to other, newer procedures related to gene expression – there are cartridges that contain the RNA measuring already half an hour, the use of biosensors to determine protein content or devices such as the nephelometer to determine immunoglobulins, etc.
In the words of the IBSAL researcher: “The most important thing, as we point out in the article, is to combine all this information with artificial intelligence to look at humans as a whole“Taking into account your immune system, the clinical situation you suffer from and the pathogen that infects you, we get so-called combination types that can help us make better decisions.”
Nevertheless, it represents a qualitative leap for clinical practice There is a consensus among the thirty researchers of the European collaborative network EGIS on the use and validity of these methodswhich are already part of everyday hospital life but are not routinely used to identify patients with sepsis and assess their severity.
“The clinician who treats these patients must be aware that if we take full advantage of them and also combine the information they offer us, there are tools that allow us to detect the disease much earlier and treat it better. “ “, concludes the researcher.
#Precision #medicine #emerged #means #treat #sepsis